Cargando…

Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia

BACKGROUND: Little research has assessed the quality of manufacturer-provided prescribing information or documented differences in key aspects of drug information among different marketed generic products of the same drug, particularly in the Middle East and Arabian Gulf. We assessed the quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebran, Nicole, Al Haidari, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074447/
https://www.ncbi.nlm.nih.gov/pubmed/16861873
http://dx.doi.org/10.5144/0256-4947.2006.192
_version_ 1783344412106948608
author Gebran, Nicole
Al Haidari, Khaled
author_facet Gebran, Nicole
Al Haidari, Khaled
author_sort Gebran, Nicole
collection PubMed
description BACKGROUND: Little research has assessed the quality of manufacturer-provided prescribing information or documented differences in key aspects of drug information among different marketed generic products of the same drug, particularly in the Middle East and Arabian Gulf. We assessed the quality of written prescribing information for selected generic drugs marketed in Saudi Arabia and manufactured in various countries of the Middle East. METHODS: We assessed the correctness and completeness of information pertaining to indications, dosage, cautions/contraindications, side effects and drug interactions in 37 package inserts for generic products registered in Saudi Arabia and manufactured in the Middle East, including atenolol (6 inserts), fluoxetine (4 inserts), ciprofloxacin (11 inserts), metformin (7 inserts), and omeprazole (9 inserts). We also described deficiencies in the quality and quantity of manufacturer-provided information that could be misleading to patients and prescribers. RESULTS: We found substantial disagreement in information between generic package inserts versus the British National Formulary and the package insert of the brand product marketed in Saudi Arabia. A cumulative average of 63±16% of drug information indicators were in agreement with these standard references. Section headings with the least conformity with study references were those related to dosage (57± 28%) and side effects (54±30%). CONCLUSION: Our results indicate that national authorities should implement appropriate measures aimed at removing misleading and incorrect information in generic package inserts and incorporating crucial prescribing information that is missing. National authorities in the Middle East and Arabian Gulf should strengthen collaboration and information interchange among each other and with international agencies to maintain common quality standards for delivering information through package inserts.
format Online
Article
Text
id pubmed-6074447
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-60744472018-09-21 Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia Gebran, Nicole Al Haidari, Khaled Ann Saudi Med Original Article BACKGROUND: Little research has assessed the quality of manufacturer-provided prescribing information or documented differences in key aspects of drug information among different marketed generic products of the same drug, particularly in the Middle East and Arabian Gulf. We assessed the quality of written prescribing information for selected generic drugs marketed in Saudi Arabia and manufactured in various countries of the Middle East. METHODS: We assessed the correctness and completeness of information pertaining to indications, dosage, cautions/contraindications, side effects and drug interactions in 37 package inserts for generic products registered in Saudi Arabia and manufactured in the Middle East, including atenolol (6 inserts), fluoxetine (4 inserts), ciprofloxacin (11 inserts), metformin (7 inserts), and omeprazole (9 inserts). We also described deficiencies in the quality and quantity of manufacturer-provided information that could be misleading to patients and prescribers. RESULTS: We found substantial disagreement in information between generic package inserts versus the British National Formulary and the package insert of the brand product marketed in Saudi Arabia. A cumulative average of 63±16% of drug information indicators were in agreement with these standard references. Section headings with the least conformity with study references were those related to dosage (57± 28%) and side effects (54±30%). CONCLUSION: Our results indicate that national authorities should implement appropriate measures aimed at removing misleading and incorrect information in generic package inserts and incorporating crucial prescribing information that is missing. National authorities in the Middle East and Arabian Gulf should strengthen collaboration and information interchange among each other and with international agencies to maintain common quality standards for delivering information through package inserts. King Faisal Specialist Hospital and Research Centre 2006 /pmc/articles/PMC6074447/ /pubmed/16861873 http://dx.doi.org/10.5144/0256-4947.2006.192 Text en Copyright © 2006, Annals of Saudi Medicine This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Gebran, Nicole
Al Haidari, Khaled
Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title_full Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title_fullStr Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title_full_unstemmed Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title_short Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
title_sort assessment of prescribing information for generic drugs manufactured in the middle east and marketed in saudi arabia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074447/
https://www.ncbi.nlm.nih.gov/pubmed/16861873
http://dx.doi.org/10.5144/0256-4947.2006.192
work_keys_str_mv AT gebrannicole assessmentofprescribinginformationforgenericdrugsmanufacturedinthemiddleeastandmarketedinsaudiarabia
AT alhaidarikhaled assessmentofprescribinginformationforgenericdrugsmanufacturedinthemiddleeastandmarketedinsaudiarabia